Cryolife Inc (CRY) Given Average Rating of “Buy” by Analysts

Cryolife Inc (NYSE:CRY) has been assigned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $23.63.

A number of equities analysts recently issued reports on the company. Canaccord Genuity reissued a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Monday, October 9th. Lake Street Capital increased their price objective on Cryolife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. TheStreet lowered Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Northland Securities reissued a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th.

In other Cryolife news, CAO Amy Horton sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total transaction of $76,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP David C. Gale sold 20,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $19.63, for a total value of $392,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 59,190 shares of company stock valued at $1,138,240. 6.00% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its position in shares of Cryolife by 30.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 149,791 shares of the medical equipment provider’s stock valued at $2,989,000 after acquiring an additional 35,247 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Cryolife by 0.7% during the 2nd quarter. Rhumbline Advisers now owns 57,291 shares of the medical equipment provider’s stock valued at $1,143,000 after acquiring an additional 387 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Cryolife by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 353,029 shares of the medical equipment provider’s stock valued at $7,042,000 after acquiring an additional 10,682 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Cryolife by 8.8% during the 2nd quarter. Legal & General Group Plc now owns 50,224 shares of the medical equipment provider’s stock valued at $1,002,000 after acquiring an additional 4,049 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Cryolife by 67.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,593 shares of the medical equipment provider’s stock valued at $171,000 after acquiring an additional 3,451 shares during the last quarter. 73.28% of the stock is owned by hedge funds and other institutional investors.

Cryolife (NYSE:CRY) opened at $18.20 on Friday. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The stock has a market capitalization of $610.60, a P/E ratio of 65.00 and a beta of 0.82. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90.

Cryolife (NYSE:CRY) last issued its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. The business had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. During the same period in the prior year, the company posted $0.13 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. analysts anticipate that Cryolife will post 0.28 earnings per share for the current fiscal year.

WARNING: “Cryolife Inc (CRY) Given Average Rating of “Buy” by Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/19/cryolife-inc-cry-given-average-rating-of-buy-by-analysts.html.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply